Slow and steady: new approach aims to help frailest myeloma patients stick with treatment
NCT ID NCT06517017
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This study tests a 'go-slow' approach for ultra-frail patients newly diagnosed with multiple myeloma. Instead of starting all drugs at once, treatment begins with just two medications (isatuximab and dexamethasone), then adds a third (lenalidomide) after two months. The goal is to see if this gentle start helps patients complete more treatment cycles and improves their quality of life. About 40 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute at the University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.